degarelix + Goserelin

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostate Cancer

Conditions

Prostate Cancer

Trial Timeline

Aug 13, 2013 โ†’ Aug 8, 2016

About degarelix + Goserelin

degarelix + Goserelin is a phase 3 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01964170. Target conditions include Prostate Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01964170Phase 3Completed

Competing Products

20 competing products in Prostate Cancer

See all competitors
ProductCompanyStageHype Score
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
36
PemetrexedEli LillyPhase 2
52
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
77
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
Abemaciclib + Placebo + Abiraterone acetate + PrednisoneEli LillyPhase 2/3
65
eFT508eFFECTOR TherapeuticsPhase 2
44
EnhertuDaiichi SankyoPhase 2
52
Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue MedicationDaiichi SankyoPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
PLX3397Daiichi SankyoPhase 2
52
Valemetostat + DarolutamideDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + Docetaxel + Prednisolone + PlaceboAstellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + Metformin HydrochlorideAstellas PharmaPhase 1
33
Enzalutamide, 160mg, 40 mg soft capsules, once dailyAstellas PharmaPre-clinical
23
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
52
enzalutamide + abiraterone acetate + prednisone + Leuprolide acetateAstellas PharmaPhase 2
52
YM155Astellas PharmaPhase 2
52